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Abstract
Background
Stunting, anemia and inflammation are frequently observed in children with end-stage renal
disease (ESRD).
Objectives
To assess anthropometric, hematological and inflammatory data and to study their potential
interrelationship in Guatemalan juveniles undergoing hemodialysis (HD) and peritoneal
dialysis (PD).
Methods
54 juveniles 7–20 years of age were recruited in FUNDANIER, Guatemala City: 27 on HD
and 27 PD. Hemoglobin, serum iron, transferrin, serum transferrin receptor (sTfR), serum
ferritin, transferrin saturation and iron-binding capacity, white blood cell count (WBC), eryth-
rocyte sedimentation rate (ESR), C-reactive protein (CRP), as well as IL-6, IL-1 and TNF-α,
weight and height were determined by standard methods. Hepcidin–25 (Hep-25) was
assessed by weak cation exchange time-of-flight mass-spectrometry.
Results
92% and 55% of HD and PD children, respectively, were stunted and 95% and 85%were ane-
mic. Among iron status biomarkers, serum ferritin wasmassively increased and significantly
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higher in the HD group compared to the PD group. Hep-25 was also greatly elevated in both
groups. 41% of HD patients showed increments in three or more inflammatory biomarkers,
while it was 2 or less in all PD subjects.
Conclusions
The degree of stunting, the prevalence and severity of anemia in Guatemalan juvenile
ESRD far exceed the national statistics for this low-income Central American country. Ferri-
tin and Hep-25 concentrations were elevated, with the latter to an extraordinary magnitude.
Additional biomarkers of inflammation not directly related to iron status were elevated as
well. The role of both disease- and environment-related factors in combination best explains
the magnitude of the biomarker abnormalities.
Introduction
Guatemala is a country in Central America, bordered to the north and to the west by Mexico,
to the northeast by Belize, to the east by Honduras and to the southeast by El Salvador. The
capital, Guatemala City, is located 1,500 m above sea level. Although Guatemala is the biggest
economy in Central America, it is among Latin American countries with the highest levels of
inequality, with poverty indicators among the highest in the region [1]. Guatemala ranks 125th
out of 187 countries on the Human Development Index (HDI) in 2014 [2]. Guatemala is con-
sidered a lower middle income developing economy with a 2013 gross domestic product
(GDP) of $54 billion [1]. Over 50% of Guatemala’s people live below the national poverty line
and 15% in extreme poverty [3].
Preventable diseases result in death, since access to quality health care is scarce. Infant mor-
tality rate is high, although it has been declining (47 per 1000 live births in 2000 to 25 per 1000
in 2012) [2].
Guatemala has the highest prevalence of under-five stunting in the Latin American region
at 49.8% in the 2008–2009 survey [4]. It also has a legacy of anemia, with pregnant women and
children under five having prevalences of 22% and 38%, respectively [5]. Recurrent diarrheal
disease [6], intestinal parasites infestation [7,8], and giardiasis [9,10], are among the environ-
mental factors leading to inflammatory stress. Rural homes have interior fireplaces and poor
ventilation with consequent indoor smoke contamination [11,12] and questions have been
raised as to the microbiological quality of the urban water supply [13,14]. A background of
poor growth, anemia and inflammation-inducing factors is present within the contemporary
Guatemalan society.
The diverse etiological factors for end-stage renal disease (ESRD) are common to industrial-
ized societies and to developing countries alike. The resources and technology for extracorpo-
real dialysis are rare in developing countries. Experiences have been reported from the Middle
East [15,16], South America [17,18], and Africa [19,20]. Nevertheless, reports on juvenile kid-
ney disease progressing to ESRD in developing countries are scarce. Malnutrition constitutes
an intertwined concern of juvenile ESRD. Conservative means to preserve failing renal function
often involve restriction of protein-rich foods, a source of nitrogenous waste. Such dietary
restriction, however, contributes to weight loss and loss of muscle and visceral mass [21]. In
children who have yet to achieve their adult stature, malnutrition is not only reflected by a low
body mass index (BMI), but also by decreased height. Stunting is a common consequence of
childhood renal disease [22,23].
ESRD in Guatemala
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Hematological abnormalities are common in ESRD. They are associated with loss of renal
parenchymal tissue, the source of erythropoietin (EPO), which upregulates erythropoiesis [24]
and with hyporesponsiveness to erythropoiesis stimulation agents [25]. EPO resistance along
with chronic inflammation in ESRD create the classical conditions for “anemia of chronic dis-
ease”mediated by increased hepcidin levels [26].
Systemic inflammation is often reflected by increased circulating C-reactive protein (CRP)
levels. Along with Interleukin-6 (IL-6) [27] and tumor necrosis factor alpha (TNF-α) [28], it is
a consistent predictor of mortality in patients with ESRD [27–29]. An important pathway to
fatal outcomes is through the elevated incidence of cardiovascular diseases [30]. This concern
of inflammatory-induced vascular damage is especially valid in children, who will experience
years of exposure [30].
The Foundation for Children with Kidney Diseases (FUNDANIER) is based in the Depart-
ment of Pediatrics of the state-run Roosevelt Hospital in Guatemala City. It has five hemodialy-
sis (HD) stations allowing for 15 sessions daily in three shifts, and a stable population of 30
patients on every-other-day HD. Home peritoneal dialysis (PD), in the form of Continuous
Ambulatory Peritoneal Dialysis (CAPD), is the other therapy offered, and it has managed up to
90 PD patients at a time.
The treatment for ESRD in FUNDANIER is free of charge. However, the hospital does not
have the means to provide the required medicine to the patients. Therefore it falls onto the
families to obtain the medications. Sixty-eight per cent of the patients in FUNDANIER come
from the metropolitan and central regions of Guatemala [31,32]. Once the rural areas are
reached, the number of children in need of RRT will increase substantially [32].
The profile of the malnutrition—hematology—inflammation complex has not been system-
atically studied in juvenile Guatemalan ESRD patients, despite the existence of factors both
intrinsic to the disease and extrinsic in the environment that bear on this triad. Our study had
the objective to investigate the impact of ESRD on growth, anemia and/or inflammation, and
to compare the findings to data reported elsewhere in order to describe the impact of back-
ground conditions in Guatemala. Differences along these parameters between HD and PD in
the FUNDANIER clinic population are assessed and discussed as well.
Subjects and Methods
Subjects
Subjects were patients with confirmed ESRD assigned to one of two modalities of extracorpo-
real dialysis at the FUNDANIER renal clinic in Guatemala City, with the prospective notion to
enroll equivalent samples for both modalities. At the time of the study, there were 27 children
receiving HD thrice-weekly, of which all were enrolled. We recruited 27 children performing
Continuous Ambulatory PD (CAPD) in the program for measurements and sample collection.
The study was approved by the Human Studies Committee of the Center for Studies of Sensory
Impairment, Aging and Metabolism (CeSSIAM) and the authorities of the Pediatrics Depart-
ment of the Roosevelt Hospital, in which FUNDANIER operates. The families of the subjects
agreed to participate voluntarily and signed an informed consent form about the benefits,
potential risks and confidentiality. Each subject was allocated with a code number for identifi-
cation. This study was registered at clinicaltrials.gov as NCT02369237.
Of the 27 HD patients, the cause of their chronic kidney disease was systemic lupus erythe-
matosus nephritis in one instance, and congenital anomalies of the kidney and urinary tract in
three others, while the remaining patients had idiopathic renal disease (n = 18) or there was no
data available from an etiological work-up (n = 5). Across the PD subsample, one subject each
had branchio-oto-renal syndrome and congenital anomalies of the kidney and urinary tract,
ESRD in Guatemala
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while the idiopathic origin and non-evaluated categories represented 77.8% and 14.8% chil-
dren, respectively.
Patients on HD received subcutaneous doses of 2,000 IU of EPO twice weekly and intrave-
nous iron (iron sucrose, 100 mg/5 mL) during dialysis sessions, aiming to maintain a monthly
control of ferritin levels between 500 and 1,000 ng/mL.
The membrane of the HD filter used is tricellulose acetate. This is not a high flux membrane.
The machines are set to have a dialysis flow of 300 mL/min. The blood flow will depend on the
size of the patient and the vascular access, but runs between 150–200 mL/min. Most of the
patients have temporal catheters as vascular access. The ultrafiltration varies according to the
weight gained between HD sessions (on average is 10–15% of the dry weight).
Although the health-care system of Guatemala cannot subsidize the purchase of erythropoi-
esis stimulating agents (ESA), erythropoietin analogs are available in the nation. Our clinic pre-
scribes ESA for the patients as a subcutaneous dose 2000 IU of EPO once or twice a week; we
estimate that about 70% of the families can provide some or all of the indicated dosage. In addi-
tion, oral iron was provided to patients on CAPD at a dosage calculated as from 2 to 6 mg/kg/
day, administered on a twice-weekly basis.
Anthropometric Measurements
All subjects had their weight (digital Health-o-Meter
1
Professional) and height measured
(SECA GmbH). HD patients were weighted before and after dialysis. Z-scores for common
anthropometric indices were calculated using the WHO Global Infobase [33].
Blood Extraction at Handling
At the end of a dialysis session, 8 mL of venous blood was drawn from blood tubing in HD
patients and 8 mL by percutaneous venipuncture in PD patients at their regular out-patient
clinical visit. Five mL were kept in a tube containing EDTA as whole blood for hematological
assessments. 1 mL was kept in plastic tubes, one designated for ferritin and CRP determination
in a local laboratory, another sub-aliquot was preserved in a cryogenic tube to determine
inflammatory biomarkers and most iron status assays in Austria; the remaining serum super-
natant was placed in a cryogenic tube for hepcidin analyses in the Netherlands. The cryogenic
tubes were stored at -80°C until shipment on dry-ice to the European collaborators.
Hematological Indices
Within 4 h of extraction, complete hematology was performed in the EDTA treated samples at
the routine laboratory of the Nuestra Señora del Pilar Hospital in an automated hematological
profile analyzer (Cell-Ruby, Ruby™, Abbott Diagnostics, Santa Barbara, Calif., USA). The
hemogram information analyzed for this study included hemoglobin (Hb) concentration,
expressed as g/dL. The Hb target for treating anemia in FUNDANIER is 12 g/dL. According to
Dirren et al, 1994 [34], the criterion for anemia for the altitude of Guatemala City (1,500 m)
should be adjusted by +0.7 g/dL in order to account for the lower oxygen tension. Therefore,
the adjusted pediatric hemoglobin (Hb) cut-off criteria for anemia at sea-level were 12.2 g/dL
for children between 5 and 12 years, and 12.7 g/dL for older subjects [34,35]. We also recorded
the hematocrit (Htc) for the adjustment of erythrocyte sedimentation rate (ESR).
Iron status Indices
Indicators of iron status, with the exception of soluble transferrin receptor (sTfR), were mea-
sured in Guatemala. Ferritin (reference range: 20–250 ng/mL) was determined by use of an
ESRD in Guatemala
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ARCHITECT i1000 (Abbott Diagnostics) at the Guatemalan hospital laboratory. Serum iron
(50–120 μg/dL), total iron-binding capacity (TIBC) (240–450 μg/dL) and transferrin (200–360
ng/mL) were measured photometrically; the ranges of the corresponding normal values for the
respective age groups are given in brackets. sTfR (1.9–5.0 mg/L) was determined in Innsbruck
by use of a Roche Hitachi 912 Chemistry Analyzer (Roche Diagnostics GmbH, Germany).
Inflammation Indices
White blood cell count (WBC) from the aforementioned clinical hemogram, was expressed in
cells per mm3. CRP was measured by nefelometry (Minineph Modelo AD500;< 5 mg/L); both
were quantified at the clinical laboratory in Guatemala City. Erythrocyte sedimentation rates
(ESR) (< 20 mm/h) were determined in Westergren vessels and adjusted for Htc. IL-6 (4.7–
300 pg/mL), IL-10 (7.8–500 pg/mL), and TNF-α (4.7–300 pg/mL) were determined in Inns-
bruck (Quantikine
1
Immunoassay; R&D-Systems, Wiesbaden, Germany).
Determination of Hepcidin-25
Serum Hep-25 was measured in the Netherlands by a combination of weak cation exchange
chromatography and time-of-flight mass spectrometry (WCX-TOF MS) [36]. An internal
standard (synthetic heavy Hep-25 stable isotope +40; custom made Peptide International Inc.)
was used for quantification [37]. Peptide spectra were generated on a Microflex LT matrix-
enhanced laser desorption/ionisation TOF MS platform (Bruker Daltonics, Bremen, Ger-
many). The lower detection limit of this method was 0.5 nM; average coefficients of variation
were 2.8% (intra-run) and 6.4% (inter-run) [37]. The median reference level of serum Hep-25
in adults is 4.5 nM for men (reference range<0.5–<14.7 nM), 2.0 nM for premenopausal
women (<0.5–<12.3 nM), and 4.9 nM (<0.5–15.6 nM) for postmenopausal women. These
reference levels for the WCX-TOF MS method are derived from those of a previously pub-
lished ELISA method, based on the regression line between the ELISA andWCX-TOF MS
results obtained for the same samples from patients without hepcidin isoforms [36,38].
Data Handling and Statistical Analyses
All values were keyed into Microsoft Excel Professional Academic 2010 for Windows. If data
were normally distributed, values are given as the arithmetic mean ± SD. If not normal in dis-
tribution, log transformation was performed on the data, and we provided the median along
with the 25th and 75th percentile. Nutritional status was assessed by calculating z-scores for
height-for-age (HAZ) of each child by means of the WHO AnthroPlus Software v.1.0.2 (2007).
Correlations were calculated according to Pearson. Linear regression analysis was carried out
to assess the relationship between serum hepcidin and other parameters. Results were com-
pared between HD and PD patients by the Mann-Whitney-Rank Sum Test for non-normally
distributed parametric data, as parameters in populations with different age, degrees of renal
failure and collateral inflammatory and hematological impairments cannot be considered nor-
mally distributed. Statistical analysis was performed using SigmaPlot
1
, Version 11.0 (2008,
Systat Software Inc, San Jose, USA).
Results
Demographic and general characteristics
The characteristics of the subjects are presented in Table 1. Fifty-four children were recruited
in FUNDANIER, Guatemala City. Twenty-seven of these children (13 females and 14 males)
had been on HD treatments for 3 weeks to 42 months, whereas another 27 (16 females and 11
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males) had been on PD therapy for periods from 1 to 58 months with the average time on dial-
ysis being significantly longer for PD (p< 0.001). The ages ranged between 7 and 20 yrs; there
was no significant difference in the mean age, height or weight between HD and PD children.
The weight of HD children was measured after dialysis.
Anthropometric classification
In reference classificatory terms, children in both subgroups were short. For the HD group
heights ranged from 96 to 160 cm (mean: 130 ± 14 cm, median: 126 cm). Correspondingly, the
range of height-for-age (HAZ) z-scores varied from -5.95 to -0.08. According to the WHO
2006 classification [33], 12 children (44.5%) were severely stunted (< -3.0 HAZ), 13 (48%)
were moderately stunted (z-score:< -2.0 to -3.0 HAZ), and 2 (7.5%) were not stunted (> -2
HAZ). Corresponding heights for the PD group ranged from 110–157 cm (mean: 134 ± 13 cm,
median: 138 cm). The range of height-for-age (HAZ) z-scores varied from -5.73 to -0.37. 33%
of the children were severely stunted, 22% were moderately stunted, and 45% were not stunted
(Fig 1). Chi-square analysis with Yates correction showed a significant difference of the pro-
portion of children in stunted categories in the HD compared to the PD subgroups (P = 0.005).
Hematological indices
Hematological measured parameters for iron and inflammatory biomarkers are presented in
Tables 2 and 3. Hb mean, SD and range values are shown in Table 2. Median Hb values were
9.3 and 9.0 g/dL for PD and HD patients respectively. Correspondingly, prevalence of anemia
is shown in Table 3. The distribution of these values is depicted in Fig 2. The altitude-adjusted
criteria for children were applied individually to the assessment of anemia [34], identifying
85% of the PD and 96% of the HD subjects as being anemic.
Laboratory biomarkers to assess the iron status are shown in the upper panels of Tables 2
and 3. The only significant differences between both treated groups were found for ferritin,
with higher increments in the HD subgroup. This distribution is illustrated in the histogram of
Fig 3. Of special note were the upper ranges of serum ferritin concentrations, with the extreme
value in the HD group exceeding 4,000 ng/mL and the highest values for PD patients exceeding
Table 1. Characteristics of the subjects.
HD (n = 27) PD (n = 27) p-
value*
Male [%] 52 41 0.29
Age [years] 12 (± 2) [7–16] 13 (± 3) [7–20] 0.49
Weight [Kg] 27 (± 8) [14–50]† 29 (± 7) [17–42] 0.35
Height [cm] 130 (± 14) [96–160] 134 (± 14) [110–157] 0.43
Height-for-age [z-scores] -3.1 (± 1.3) [-5.9–-0.1] -2.6 (± 1.4) [-5.7–-0.4] 0.16
Time on current dialysis
[mo]
3.0 (95% CI: 2.6; 9.4) [0.75–42] 9.0 (95% CI: 8.5; 15.7) [1–32] 0.004
Total time on dialysis [mo] 4.0 (95% CI: 4.1; 14.0) [0.75–
45]
14.0 (95% CI: 9.8; 20.4) [1–
58]
0.031
HD, hemodialysis; PD, peritoneal dialysis; mo, months.
Data are means (± SD), median (95% Conﬁdence Intervals) and [range].
*P values determined according to t-test for normally distributed continuous variables, Mann-Whitney rank-
sum tests for non-normally distributed continuous variables.
†Weight measured after hemodialysis.
doi:10.1371/journal.pone.0140062.t001
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Fig 1. Histogram.Distribution of HAZ (n = 53). Grey bars represent peritoneal dialysis patients (n = 26) and
dark grey bars represent hemodialysis patients (n = 27). Z-scores values between 0 and -1 = normal;
between -1 and -2 = stunting; between -2 and -3, moderate stunting; and < -3.1 = severe stunting.
doi:10.1371/journal.pone.0140062.g001
Table 2. Central tendency and variance values for iron status and inflammatory biomarkers in hemo-
dialysis and peritoneal dialysis patients.
HD (n = 27) PD (n = 27) p-value*
Iron Status Biomarker
Hb [g/dL] 9.0 (± 2.0) [3.8–16.5] 9.9 (± 2.7) [6.0–16.5] 0.17
Serum iron [μg/dL]† 65 [24–148] 65 [30–175] 0.29
TIBC [μg/dL] 282 [143–488] 253 [154–340] 0.53
Transferrin [ng/mL]† 21 [7–63] 28 [12–103] 0.23
sTfR [mg/dL] 3.4 [1.8–6.1] 2.7 [0.3–7.1] 0.14
Ferritin [ng/ML]† 602 [193–4,113] 458 [17–1,506] 0.01
Hep-25 [nM] 36 [2–131] 43 [0.5–140] 0.68
Inﬂammatory Biomarker
WBC [103/μL] 5.2 [2.7–14.1] 6 [4–12] 0.04
ESR [mm/h] 97 [16–145] 75 [2–125] 0.03
CRP [mg/L] [< 5–70] ǂ [< 5–62] ǂ NA
IL-6 [pg/mL] 7 [3–335] 3 [1–13] < 0.001
IL-10 [pg/mL] 14 [5–690] 6 [2.5–65] < 0.001
TNF-α [pg/mL] 6.5 [0–122] [0–9] ǂ < 0.001
HD, hemodialysis; PD, peritoneal dialysis; Hb, hemoglobin; TIBC, total iron binding capacity; sTfR, soluble
transferrin receptor; Hep-25; hepcidin-25; WBC, white blood cell count; ESR, erythrocyte sedimentation
rate; CRP, C-reactive protein; IL-6, Interleukin-6; IL-10, Interleukin-10; TNF-α, tumor necrosis factor alpha;
NA, not available.
Data are presented as means (± SD), or median and [minimum-maximum].
* P values determined according to t-test for normally distributed continuous variables, Mann-Whitney rank-
sum tests for non-normally distributed continuous variables.
† Log transformed variables.
ǂ Only presented the range.
doi:10.1371/journal.pone.0140062.t002
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1,500 ng/mL. Over 30% of values were outside of the normal cut-off boundaries for iron-status
indicators with the exceptions of sTfR in the HD subgroup and of TIBC in the PD subgroup.
Hep-25 concentrations ranged from 0.5 to 140 nM for PD and 2 to 131 nM for HD patients
(p = 0.7). Comparing these concentrations to the normal range (< 0.5 to 14.6 nM), 81.5% of
PD and 85.2% of HD patients had elevated Hep-25 concentrations (Table 3). Table 4 presents
the correlation of Hep-25 with the iron and inflammatory variables (Spearman test). Signifi-
cant positive correlations were observed between Hep-25 and serum iron-concentrations,
transferrin and ferritin for PD. Whereas negative correlations were observed between Hep-25
and hemoglobin, TIBC and serum transferrin receptor in the same group. These correlations
were not significant for the HD patients. Accordingly, Hep-25 correlated well with ferritin
(r = 0.77; p< 0.01) and serum iron (r = 0.56; p< 0.01) in PD (Fig 4), but not in HD patients
(Fig 5) when analyzed by the Pearson test.
Inflammatory Biomarkers
Ferritin and hepcidin, discussed with the iron-status markers above, are also acute-phase reac-
tants and are, thus, closely related to concentrations of inflammatory biomarkers shown in
Tables 2 and 3.
The percentage of abnormally elevated biomarkers was higher in numerical terms for HD in
5 out of 6 (as well as for ferritin and hepcidin), and this was significant for ferritin (p = 0.02)
and TNF-α (p = 0.002 Chi-square). The only exception was the mild reversal for ESR, being 5
percentage-points more frequently elevated on the PD side. As shown in Fig 6, the clustering of
Table 3. Percentage of subjects with values outside of the normal range for biomarkers in hemodialy-
sis and peritoneal dialysis patients.
Percentage abnormal (%)
HD (n = 27) PD (n = 27) p-value*
Iron Status Biomarker
Hb [g/dL] 96.3 81.5 0.35
Serum iron [μg/dL] 33.3 37.0 1.0
TIBC [μg/dL] 55.5 22.2 0.02
Transferrin [ng/mL] 51.8 44.4 0.79
Transferrin saturation [%] 59.2 37.0 0.17
sTfR [mg/dL] 11.1 33.3 0.10
Ferritin [ng/mL] 92.6 63.0 0.02
Hep-25 [nM] 85.2 81.5 1.0
Inﬂammatory Biomarker
WBC [103/μL] 29.6 11.1 0.17
CRP [mg/L] 25.9 3.7 0.05
ESR [mm/h] 88.8 92.6 1.0
IL-6 [pg/mL] 40.7 3.7 0.23
IL-10 [pg/mL] 25.9 14.8 0.5
TNF-α [pg/mL] 11.1 0 0.002
HD, hemodialysis; PD, peritoneal dialysis; Hb, hemoglobin; TIBC, total iron binding capacity; sTfR, soluble
transferrin receptor; Hep-25, hepcidin-25; WBC, white blood cell count; CRP, C-reactive protein; ESR,
erythrocyte sedimentation rate; IL-6, Interleukin-6; IL-10, Interleukin-10; TNF-α = tumor necrosis factor
alpha.
* P-value was calculated with original data.
doi:10.1371/journal.pone.0140062.t003
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concurrently elevated inflammatory biomarkers in the same patient shows a marked effect:
whereas 100% of PD subjects had 2 or fewer elevations, 11 of 27 HD patients (41%) showed 3
or more parameters elevated. Statistical analysis is not appropriate, giving the nature of the dis-
tribution, but we get the visual impression that the cumulative burden of systemic inflamma-
tion is greater in the HD group.
Discussion
End-stage renal disease (ESRD) in children presents a multi-level challenge for a developing
country like Guatemala. The resources to support facilities for care and therapy in pediatric
nephrology are severely limited. As discussed above, moreover, background factors in Guate-
mala involving diet, environment and economics can be argued to already provide a “head
Fig 2. Histogram.Distribution of whole blood hemoglobin concentrations in g/dL of all patients (n = 54). Grey
bars represent peritoneal dialysis patients (n = 27) and dark grey bars represent hemodialysis patients
(n = 27). Vertical dashed lines show the cut-off values for hemoglobin in Guatemala for children between 5 to
12 years of age (12.2 g/dL) and children between 12 and 15 years of age (12.7 g/dL).
doi:10.1371/journal.pone.0140062.g002
Fig 3. Histogram.Distribution of ferritin concentrations in ng/mL of all patients (n = 54). Grey bars represent
peritoneal dialysis patients (n = 27) and dark grey bars represent hemodialysis patients (n = 27).
doi:10.1371/journal.pone.0140062.g003
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start” down the slope towards poor growth, anemia and inflammation, the cardinal manifesta-
tions of interest in this study. The background states for the three kinds of manifestation were
postulated to interact with renal-based factors in an additive—if not synergistic—manner, to
produce growth retardation, hematological deficits and more rigorous inflammatory response
in the extreme end of what has been reported in the literature.
Comparative issues of linear growth
The stunting rate in Guatemala of 49.8% for children under 5 years of age is the third highest
reported worldwide [4]. For comparison, average stunting rates of 38%, 28% and 14% have
been reported for Africa, Asia and Latin America, respectively [33]. Underlying causes under
discussion range from preconceptual and prenatal factors, such as short stature of the mother,
early age of first delivery, maternal underweight and anemia, to tobacco use and indoor pollu-
tion. Thus, the adolescents in our study could well have gone through a period of retarded
growth during this vulnerable prenatal period. In addition, there are postnatal influences, such
as inadequate nutrition and frequent infections [39]. Intergenerational transmission of stunt-
ing is mediated by shared genetic characteristics, inherited poverty, and by epigenetic influ-
ences [40–43]. Growth faltering begins soon after birth, reaching a maximum at 2 years of age
after which the extent of stunting seems to remain at the same level [44,45]. Impaired school
performance and increased morbidity and mortality are often associated with stunting. The
prevalence and extent of stunting in Guatemalan ESRD juveniles are significantly higher than
observed in a community trial in Guatemala City during the same period which argues for a
predominant contribution of renal impairment to the stunting rates observed in the present
study. Causes of stunting seem closely related to nutrition, as shown by the positive effect of
nutritional interventions in Guatemala [46], and by improved height and body proportions in
Mayan children who moved from Guatemala to the US [47].
Table 4. Spearman correlation coefficients of Hep-25 with other variables.
HD (n = 27) PD (n = 27)
Variable r p-value r p-value
Age [years] 0.14 0.47 -0.2 0.23
Weight [Kg] 0.13 0.5 -0.2 0.29
Height [cm] 0.17 0.4 -0.4 0.03
Hb [g/dL] 0.08 0.68 -0.4 0.02
Serum iron [μg/dL] -0.1 0.56 0.6 0.002
TIBC [μg/dL] -0.2 0.31 -0.3 0.07
Transferrin [ng/mL] 0.06 0.7 0.6 < 0.001
sTfR [mg/dL] -0.3 0.18 -0.6 < 0.001
Ferritin [ng/mL] 0.2 0.26 0.9 < 0.001
WBC [103/μL] 0.06 0.77 0.2 0.2
CRP [mg/L] 0.3 0.09 -0.3 0.16
ESR [mm/h] 0.3 0.15 0.3 0.15
IL-6 [pg/mL] 0.14 0.47 0.1 0.44
IL-10 [pg/mL] 0.2 0.36 -0.1 0.51
TNF-α [pg/mL] 0.13 0.48 0.2 0.32
HD, hemodialysis; PD, peritoneal dialysis; Hb, hemoglobin; TIBC, total iron binding capacity; sTfR, soluble
transferrin receptor; WBC, white blood cell count; CRP, C-reactive protein; IL-6, Interleukin-6; IL-10,
Interleukin-10; ESR, erythrocyte sedimentation rate; TNF-α = tumor necrosis factor alpha.
doi:10.1371/journal.pone.0140062.t004
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Fig 4. Scatter Plot. Correlation in PD patients betweenA. ferritin and Hep-25 (r = 0.77; P < 0.01); B. serum
iron and Hep-25 (r = 0.56; P < 0.01); andC. CRP and Hep-25 (r = -0.23; P = 0.256).
doi:10.1371/journal.pone.0140062.g004
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Fig 5. Scatter Plot. Correlation in HD patients betweenA. ferritin and Hep-25 (r = 0.04; P = 0.82);B. serum
iron and Hep-25 (r = 0.05; P = 0.79); andC. CRP and Hep-25 (r = 0.31; P = 0.12).
doi:10.1371/journal.pone.0140062.g005
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Uremic growth failure is multifactorial, including causes like energy malnutrition, water and
electrolyte disturbances, metabolic acidosis, renal anemia and somatotropic and gonadotropic
hormone disturbances [48]. Half of the patients with ESRD in childhood attain adult’s height
below the third centile [49]. Inflammation and impaired energy metabolism reduce appetite,
which, in a vicious cycle, reduces the supply of vitamins C, B6, B12 and folate [50]. US data
show that the extent of stunting does not respond to dialysis [51,52], while renal transplantation
before or during the prepupertal growth period induces moderate catch-up growth [52]. Growth
failure has long been recognized in children with chronic renal failure [53]. However, data on
the prevalence of stunting in ESRD are scarce, particularly in developing countries. Approxi-
mately 50% of children who develop ESRD in Europe before the age of 15 were stunted [54],
which compares to 93% stunted juveniles in our cohort (45% severe plus 48% moderate stunt-
ing). These figures suggest a much higher prevalence of stunting in Guatemalan than in Euro-
pean ESRD patients. The comparison remains incomplete though, as we do not have sufficient
access to the quoted European database to compare the different degrees of stunting. Average
HAZ scores in US ESRD children varied between -1.81 ± 0.05 and -2.18 ± 0.12 [51], which
again signals considerably less stunting than the average of -3.1 ± 1.3 and -2.6 ± 1.4 found in
Guatemalan children on HD and PD, respectively.
Bone growth is the most essential determination of height, requiring the optimal conditions
for elongation to achieve genetic potential in stature. Skeletal elongation is largely a hormon-
ally-mediated process, but the mineralization disruption of renal osteodystrophy, discussed in
the context of anemia [55,56], could limit the efficacy of the trophic hormone signaling due to
the limitation of mineral substrates for new bone formation.
Comparative issues of hematological status
The average prevalence of anemia in Guatemalan children is 38% [5,57]. About half of the ane-
mia cases in developing countries go along with low ferritin values indicating iron deficiency
anemia (IDA) [58,59]. High dietary phytate and polyphenol content which impair iron bio-
availability have been discussed as underlying causes, in combination with low intake rates of
meat, fish, poultry, and fruits rich in ascorbic- and polyoxicarbonic acids to counteract this
impairment [60]. Anemia in combination with high ferritin concentrations has been termed
non-IDA and accounts for the other half of anemias in developing countries. These anemias
were discussed to relate to lack of essential micronutrients other than iron, such as vitamins A,
B2, B12, C or Cu, or Zn [58] or to inflammation.”Anemia of inflammation”, also termed
Fig 6. Frequency of concurrently elevated inflammatory biomarkers in the same HD and PD patients.
doi:10.1371/journal.pone.0140062.g006
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“Anemia of chronic diseases” (ACD), goes along with increased hepcidin concentrations that
reduce duodenal iron absorption and increase iron sequestration in the reticuloendothelial sys-
tem. Both effects are supposed to serve as host-defense mechanisms in infection, but restrict
iron procurement to erythropoiesis in parallel [26].
Anemia in ESRD is regarded to have traits of ACD showing increased IL-6 and hepcidin
concentrations, so that iron is rendered scarce for erythropoiesis. This may act additively with
the nutrition-dependent mechanisms of anemia in developing countries described above. Glo-
merular hepcidin filtration is impaired in renal failure, which contributes to increased hepcidin
concentrations in ACD. Consequently, hepcidin can be successfully reduced by HD [61–64].
However, post-dialysis levels were back to pre-dialysis levels within one hour after the end of
the dialysis session [65]. Another major cause of anemia in ESRD is EPO-deficiency [66]. Still,
EPO administration fails to reduce anemia in 10% of patients. It has been speculated that Hep-
25 concentrations in serum might predict the response to EPO administration [66]. However,
in humans the association between hepcidin and erythropoiesis stimulating agents (ESA)
response has not been definitely demonstrated [67]. Moreover, hepcidin seems to inhibit eryth-
ropoietic colony formation directly [68] and erythrocyte survival is shortened due to hemolysis
in patients with ESRD, likely also in the dialysis circuit [69,70]. In addition, sufficient iron pro-
curement was shown to be helpful in the treatment of anemia in ESRD [71].
A potential contributor to anemia could be the renal osteodystrophy seen in ESRD patients,
in which the elevation of circulating phosphate produces decreased levels of calcium and subse-
quent elevated parathyroid hormone (PTH) [72]. A prominent feature of this condition is
fibrosis in the bone marrow, which crowds out the medullar space for the development of red
cell precursors. Controlling the consequences of accumulation of phosphorus is the therapeutic
strategy to avert its leaching of bone calcium. Our patients are prescribed a daily dose of
0.25 μg of 1-alpha vitamin D3 in order to create a negative feedback to PTH, and with calcium
carbonate tables to enhance exogenous calcium uptake and to chelate the phosphorus of the
diet. Therapy is gauged by PTH maintained at least at three times the 75 pg/mL basal concen-
tration. In analyzing the respective assay data available at the time of study across the 54
patients, only 4 of 19 PTH values failed to exceed the 225 pg/mL threshold. Hypocalcemia
(< 8.0 mg/dL) was only seen twice among 16 assays, but hyperphosphatemia (>5.0 mg.dL)
was present in 45% if the 22 values reviewed (data not shown). This information opens the way
for fibrotic issues of the bone marrow to be affecting red cell production in some individuals.
Independent of the underlying causes, recent trials [73] signal a higher frequency of fatal
and non-fatal cardiac events in individuals with normal as compared to reduced hemoglobin
and hematocrit concentrations; this casts doubt on whether reducing prevalence of anemia
should be a primary goal of treatment in ESRD, although it is prudent to support Hb concen-
trations at a certain minimal level, even within the anemic range.
Iron status regulation and inflammatory burden
Hepcidin measurements are not standardized and, therefore, absolute hepcidin levels cannot
be reliably compared if obtained by different methods [74]. Adult patients with ESRD from dif-
ferent parts of the world often present with small to massive hepcidin elevations [62–64,75]. In
a study from California, USA, using an immunoassay for serum hepcidin, the median values of
hepcidin were 26 times higher in juvenile hemodialysis patients (average age of 15 y) than
those in age-equivalent control children with normal renal function [76]. In adolescents and
adults on hemodialysis in California, USA [63], the adults had a three-fold higher hepcidin
concentration than juveniles, which was observed in control as well as in HD subjects. In con-
trast, with the WCX-TOF-MS method from Nijmegen, the relationship Dutch adults on
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hemodialysis [64] and children of both groups in this study was reversed. The median hepcidin
value of 9.4 nM in adults was one-fourth that in Guatemalan juveniles on HD and one-fifth
that in those on PD. Two differences between these situations may be responsible for this
inversion. Firstly, lower hygienic status and frequent exposure to infectious microbes as well as
noise and pollution may increase stress and the inflammatory burden in Guatemala. The latter
should increase biomarkers such as CRP, leukocytes, and cytokines in Guatemalan children
which, in turn, is likely to raise hepcidin concentrations in parallel, aggravate anemia and
impair prognosis of children with ESRD. CRP concentrations, for instance, were much higher
in Guatemalan juveniles than in Dutch adults on HD (26 mg/L vs. 8 mg/L). Secondly, paren-
teral iron dosing in Guatemalan children on HD lead to an average ferritin level of 600 ng/mL
while Dutch adults showed a median ferritin concentration of 270 ng/mL. Guatemalan patients
did not receive any blood transfusion, which would explain the iron overload in this popula-
tion. Inflammatory burden and iron supplementation differ markedly between these two
groups which can well overrule age-related differences.
Correlation between plasma concentrations of Hep-25 and ferritin in
ESRD
In Dutch adults using the same WCX-TOF MS Hep-25 assay [64] as in the present study,
those patients with chronic kidney disease not yet on dialysis showed a high correlation coeffi-
cient (r = 0.74) between ferritin and hepcidin concentrations. Those patients on HD for a
median period of 26 mo, had an r = 0.79. This is in accordance to the expectation, as inflamma-
tion and high iron status stimulate hepcidin synthesis in parallel [67,77]. Focusing on the
hemodialysis patients in the Dutch study, significant correlations were also detected between
Hep-25 and Hb, serum iron, transferrin and CRP, but not with transferrin saturation. In con-
trast, in the present study of juvenile Guatemalans on HD, no significance was found for the
association of any of the aforementioned variables (Table 4). However, in the PD subgroup, we
replicated significant correlations with all common variables mentioned above, except CRP
(Table 4). Scattergrams of associations between Hep-25, ferritin and serum iron are shown in
the respective panels of Fig 6. In our PD group, moreover, the association was also significant
with sTfR as well as with height in cm (Table 4).
One possible explanation for these differences is, again, the differential use of parenteral
iron supplementation. Our PD patients received oral iron. In the study by Peters et al [64],
adult subjects received no i.v. iron during hemodialysis, resulting in a median ferritin concen-
tration of ~270 ng/mL. Our HD patients were given parenteral iron during dialysis sessions,
aiming to maintain ferritin levels between 500 and 1000 ng/mL and succeeding to establish a
median ferritin concentration of ~600 ng/mL (Table 2). These values are over twice as high as
those observed in Dutch adults [64] and suggest liver iron overload [78,79]. In the Guatemalan
PD children iron was given orally. Thus, the extent of its absorption is under hepcidin control
and will be reduced in inflammation and with high iron status. We speculate that the lesser
exposure to iron in our PD series and in the Dutch adults produced a situation in which ferritin
was faithfully reflecting iron stores, and hepcidin was responding to regulatory needs. The
higher iron doses may have led to a situation in which both the iron-storage and the low-grade
inflammation indicated by the corresponding inflammatory biomarkers have an impact on cir-
culating ferritin values. This is compatible with the obviously higher inflammatory burden in
the HD patients shown in Fig 5. Further research is needed to determine if the administration
of iron preparations to ESRD patients produces adverse effects and aggravates other comorbid-
ities in the patients (viral hepatitis, cardiovascular disease, infections).
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Interplay between inflammatory burden, stunting and anemia
In children on HD the high number of increased inflammatory markers indicates a higher level
of inflammation than in PD. Transgenic mice with markedly increased IL-6 levels show a nega-
tive correlation between IL-6 and insulin-like growth factor I (ILGF I) and are stunted [80].
This may be one of the mechanisms by which inflammation reduces growth. Correspondingly,
TNF-α concentration correlated with the degree of stunting in girls, and IL-6, CRP and insulin
resistance correlated with the degree of stunting and adiposity in boys in South Africa [81].
This corresponds well to the higher degree of stunting in the HD as compared to PD juveniles
of our study with less indication for inflammation (Figs 1 and 4). Higher stunting rates in HD
children may also explain why hemoglobin concentrations showed no differences between the
treatment groups in spite of markedly higher hepcidin values in the HD children. Blood vol-
ume is assumed to account for approximately 3% of body weight. Thus, smaller children have a
lower blood volume and the same amount of hemoglobin will lead to a higher hemoglobin con-
centration. This corresponds, at least in part, to Golden’s hypothesis of stunting as an adaption
to micronutrient deficiency [82].
One of the factors for a greater burden of inflammatory stress in the HD group, as compared
to the PD group, could theoretically have related to the cumulative duration of renal replace-
ment therapy. However, the data do not support such a proposition (Table 1). In fact, paradox-
ically, the PD patients had been receiving RRT for over three times as long (14 mo) as those on
HD (4 mo), such that duration, per se, is not a viable candidate factor for determining inflam-
matory intensity. With respect to peritonitis, this would be a candidate factor contrary to that
found in this study, namely one of a greater inflammatory state in the PD series. As expected,
some HD children have been on PD earlier; records showed that of the seven patients on HD
who had previously undergone PD, two had a history of peritonitis episodes. Only 10 of the 27
patients of the study currently on PD were free of a peritonitis history, with the incidence of
episodes ranging from 1 to 32 in the remaining subjects. Finally, vascular access for the HD
series is a candidate factor in differential inflammation. In Guatemala, hemodialysis does not
come with the luxury of permanent arterio-venous fistulas and temporary catheters must be
used. This may represent a partial explanation for enhanced inflammatory stress in the HD
group.
Exceptional behavior of hemoglobin, ferritin and hepcidin concentrations
Finally, we can take a closer look into the subset of 4 ESRD patients on PD who did not have
anemia, as shown in the hemoglobin distribution histogram in Fig 2. These hemoglobin values
are in the right hand shoulder of the distribution curve above 12.7 g hb/dL, along with the one
non-anemic patient from the HD group. These patients had low hepcidin values, diverging
from the almost generalized high-hepcidin response in all other subjects in both dialysis
modes. Similarly, the ferritin values were< 400 ng/mL in all non-anemic PD subjects (16.5;
61.6; 120.7; and 322.6 ng/mL). Obviously, the iron-transport blockade, mediated by hepcidin,
is not operating in these 4 exceptional subjects, allowing their bone marrows to take up iron
and effectively utilize it for erythropoiesis which avoids anemia. The extents of renal failure as
well as the time on dialysis are in the same order of magnitude as in the anemic patients. Why
the vicious cycle of renal failure and anemia is not operating in these patients requires future
research.
Strengths and limitations of the study
Among the strengths of the study is the comparably large scope of collected data, consisting of
8 hematological variables, specific measurement of Hep-25 by mass spectrometry among them,
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and 6 inflammatory variables. Moreover, they are all collected in a total of 54 children from a
developing country; this number of patients on dialysis is in the same order of magnitude as in
the study of Peters et al [64]. As FUNDANIER is the only center for pediatric dialysis in Guate-
mala, this provides an assessment of close to all children on dialysis in this country at the point
in time of the trial. This relates to the disadvantage that our patients were not randomly allo-
cated to HD or PD treatment, but for the best of the patients as for as achievable by available
means. The different modes of iron treatment in the PD and HD group is another disadvan-
tage, as it impairs direct comparability of the two treatment groups.
Conclusions and Perspectives
Though to reduce extent and prevalence of anemia improves well-being, it seems to impair
rather than to improve the patients’ life expectancy [73]. An expected finding was the much
higher hepcidin and ferritin concentration in Guatemalan children as compared to Dutch
adults. Future research should probe the underlying causes which may be found in the higher
iron procurement and/or in the higher inflammatory burden of the Guatemalan children likely
as a consequence of repeated exposure to infectious hazards. The impact of different iron dos-
ages and different ways of iron administration in PD and HD patients impairs the direct com-
parison between the treatments, though it reflects presently used treatment strategies. Finally, 4
PD children showed no anemia and 3 of them showed no increased hepcidin or ferritin values;
this triad of findings in itself fits nicely together. However, anemia, iron metabolism and
inflammation in those 4 patients behave differently from the majority of the children with
ESRD in this study. Speculation on the causes underlying this less dramatic clinical course may
be differences in iron procurement, in the extent of inflammation or in genetic aberration of
second messenger pathways of hepcidin regulation. It seems promising to investigate such
“black swan” events in more detail when looking for new modes of treatment for children on
ESRD.
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